Davuluri Gangarao, Allawy Allawy, Thapaliya Samjhana, Rennison Julie H, Singh Dharmvir, Kumar Avinash, Sandlers Yana, Van Wagoner David R, Flask Chris A, Hoppel Charles, Kasumov Takhar, Dasarathy Srinivasan
Department of Pathobiology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Department of Chemistry, Cleveland State University, SR 364, 2351 Euclid Avenue, Cleveland, OH, 44115, USA.
J Physiol. 2016 Dec 15;594(24):7341-7360. doi: 10.1113/JP272796. Epub 2016 Oct 23.
Hyperammonaemia occurs in hepatic, cardiac and pulmonary diseases with increased muscle concentration of ammonia. We found that ammonia results in reduced skeletal muscle mitochondrial respiration, electron transport chain complex I dysfunction, as well as lower NAD /NADH ratio and ATP content. During hyperammonaemia, leak of electrons from complex III results in oxidative modification of proteins and lipids. Tricarboxylic acid cycle intermediates are decreased during hyperammonaemia, and providing a cell-permeable ester of αKG reversed the lower TCA cycle intermediate concentrations and increased ATP content. Our observations have high clinical relevance given the potential for novel approaches to reverse skeletal muscle ammonia toxicity by targeting the TCA cycle intermediates and mitochondrial ROS.
Ammonia is a cytotoxic metabolite that is removed primarily by hepatic ureagenesis in humans. Hyperammonaemia occurs in advanced hepatic, cardiac and pulmonary disease, and in urea cycle enzyme deficiencies. Increased skeletal muscle ammonia uptake and metabolism are the major mechanism of non-hepatic ammonia disposal. Non-hepatic ammonia disposal occurs in the mitochondria via glutamate synthesis from α-ketoglutarate resulting in cataplerosis. We show skeletal muscle mitochondrial dysfunction during hyperammonaemia in a comprehensive array of human, rodent and cellular models. ATP synthesis, oxygen consumption, generation of reactive oxygen species with oxidative stress, and tricarboxylic acid (TCA) cycle intermediates were quantified. ATP content was lower in the skeletal muscle from cirrhotic patients, hyperammonaemic portacaval anastomosis rat, and C2C12 myotubes compared to appropriate controls. Hyperammonaemia in C2C12 myotubes resulted in impaired intact cell respiration, reduced complex I/NADH oxidase activity and electron leak occurring at complex III of the electron transport chain. Consistently, lower NAD /NADH ratio was observed during hyperammonaemia with reduced TCA cycle intermediates compared to controls. Generation of reactive oxygen species resulted in increased content of skeletal muscle carbonylated proteins and thiobarbituric acid reactive substances during hyperammonaemia. A cell-permeable ester of α-ketoglutarate reversed the low TCA cycle intermediates and ATP content in myotubes during hyperammonaemia. However, the mitochondrial antioxidant MitoTEMPO did not reverse the lower ATP content during hyperammonaemia. We provide for the first time evidence that skeletal muscle hyperammonaemia results in mitochondrial dysfunction and oxidative stress. Use of anaplerotic substrates to reverse ammonia-induced mitochondrial dysfunction is a novel therapeutic approach.
高氨血症发生于肝脏、心脏和肺部疾病,且肌肉中氨浓度升高。我们发现,氨会导致骨骼肌线粒体呼吸减少、电子传递链复合体I功能障碍,以及较低的NAD/NADH比值和ATP含量。在高氨血症期间,复合体III的电子泄漏会导致蛋白质和脂质的氧化修饰。高氨血症期间三羧酸循环中间产物减少,而提供一种细胞可渗透的α-酮戊二酸酯可逆转较低的三羧酸循环中间产物浓度并增加ATP含量。鉴于通过靶向三羧酸循环中间产物和线粒体活性氧来逆转骨骼肌氨毒性的新方法具有潜力,我们的观察结果具有高度临床相关性。
氨是一种细胞毒性代谢产物,在人类中主要通过肝脏尿素生成来清除。高氨血症发生于晚期肝脏、心脏和肺部疾病以及尿素循环酶缺乏症。骨骼肌氨摄取和代谢增加是非肝脏氨清除的主要机制。非肝脏氨清除通过线粒体中由α-酮戊二酸合成谷氨酸而发生,从而导致物质外流。我们在一系列人类、啮齿动物和细胞模型中展示了高氨血症期间骨骼肌线粒体功能障碍。对ATP合成、氧气消耗、氧化应激下活性氧的生成以及三羧酸(TCA)循环中间产物进行了定量分析。与适当的对照相比,肝硬化患者、高氨血症门腔静脉吻合大鼠和C2C12肌管的骨骼肌中ATP含量较低。C2C12肌管中的高氨血症导致完整细胞呼吸受损、复合体I/NADH氧化酶活性降低以及电子传递链复合体III处发生电子泄漏。与对照相比,在高氨血症期间观察到较低的NAD/NADH比值以及三羧酸循环中间产物减少。高氨血症期间活性氧的生成导致骨骼肌羰基化蛋白质和硫代巴比妥酸反应性物质含量增加。一种细胞可渗透的α-酮戊二酸酯可逆转高氨血症期间肌管中较低的三羧酸循环中间产物和ATP含量。然而,线粒体抗氧化剂MitoTEMPO并不能逆转高氨血症期间较低的ATP含量。我们首次提供证据表明骨骼肌高氨血症会导致线粒体功能障碍和氧化应激。使用补充性底物来逆转氨诱导的线粒体功能障碍是一种新的治疗方法。